CollPlant Secures Korean Patent Through 2039, Targets $6 B Global Filler Market
CollPlant Biotechnologies secured Korean Patent Office allowance for its photocurable dermal filler, extending protection through 2039 in a key aesthetic market. The light-activated rhCollagen and hyaluronic acid formulation forms injectable scaffolds for tissue augmentation, strengthening IP coverage across major jurisdictions and positioning the company in the $6 billion global filler market.
1. Korean Patent Allowance
The Korean Patent Office has allowed CollPlant’s application for its photocurable dermal filler technology, granting exclusive rights in South Korea through 2039. This milestone secures intellectual property in one of the world’s most dynamic aesthetic medicine markets.
2. Photocurable Filler Technology
CollPlant’s formulation combines chemically modified recombinant human collagen with a hyaluronic acid-based filler, engineered for extrusion through a 27-gauge needle and in situ polymerization via external light activation. The result is a supportive scaffold designed for long-term contour stability.
3. Market Positioning
By securing Korean patent protection, CollPlant reinforces its strategy to enter the over $6 billion global injectable soft-tissue filler market. The allowance enhances the company’s commercial appeal and underpins future clinical development and licensing opportunities in high-value aesthetic segments.
4. Global Intellectual Property Coverage
This Korean allowance follows granted patents in the United States, Europe, China, Brazil, Australia and Israel, with further applications pending. The broad IP portfolio strengthens CollPlant’s competitive moat and positions it for global market penetration.